重症监护中抗血栓药物合理使用共识(CURATIVE):领域1——定义风险人群
该共识采用人群-暴露-比较-结局(PECO)格式,由工作表作者进行综合检索并总结证据,经领域主席审核后通过德尔菲调查达成最终推荐。评估的疾病包括免疫介导性溶血性贫血、蛋白丢失性肾病、胰腺炎、糖皮质激素治疗、肾上腺皮质功能亢进、肿瘤、脓毒症、脑血管病和心脏病。高风险定义为犬免疫介导性溶血性贫血或蛋白丢失性肾病、猫心肌病伴相关危险因素、或犬/猫存在>1种疾病或血栓危险因素;低或中风险定义为犬或猫仅有单一危险因素或疾病,或已知危险因素疾病可能在治疗后数天至数周内消退。这些疾病与血栓的关联为后续领域的处方推荐提供了基础。
要点
- 犬免疫介导性溶血性贫血或蛋白丢失性肾病被定义为血栓高风险。
- 猫心肌病伴相关危险因素被定义为血栓高风险。
- 犬或猫存在>1种疾病或血栓危险因素被定义为血栓高风险。
- 犬或猫仅有单一危险因素或疾病被定义为低或中风险。
- 已知危险因素疾病可能在治疗后数天至数周内消退的犬或猫被定义为低或中风险。
适用人群与场景
- 评估的疾病人群包括:免疫介导性溶血性贫血、蛋白丢失性肾病、胰腺炎、糖皮质激素治疗、肾上腺皮质功能亢进、肿瘤、脓毒症、脑血管病和心脏病。
诊断标准与关键阈值
- 血栓高风险:犬免疫介导性溶血性贫血或蛋白丢失性肾病。
- 血栓高风险:猫心肌病伴相关危险因素。
- 血栓高风险:犬或猫存在>1种疾病或血栓危险因素。
- 低或中风险:犬或猫仅有单一危险因素或疾病。
- 低或中风险:犬或猫已知危险因素疾病可能在治疗后数天至数周内消退。
研究设计与关键结果
- 共识制定采用PECO格式提出问题,工作表作者综合检索并总结证据,创建指南推荐,经领域主席审核后通过德尔菲调查达成共识。
- 评估的疾病包括免疫介导性溶血性贫血、蛋白丢失性肾病、胰腺炎、糖皮质激素治疗、肾上腺皮质功能亢进、肿瘤、脓毒症、脑血管病和心脏病。
- 定义的高风险人群包括:犬免疫介导性溶血性贫血或蛋白丢失性肾病、猫心肌病伴相关危险因素、或犬/猫存在>1种疾病或血栓危险因素。
- 定义的低或中风险人群包括:犬或猫仅有单一危险因素或疾病、或已知危险因素疾病可能在治疗后数天至数周内消退。
证据类型、等级与局限
- 证据类型:共识(指南)。
- 共识形成方法:PECO格式、综合检索、工作表作者总结证据、领域主席审核、德尔菲调查达成共识。
- 局限:原文未报告局限性。
对床旁实践的改变
- 临床可根据共识定义识别血栓高风险犬或猫:犬免疫介导性溶血性贫血、犬蛋白丢失性肾病、猫心肌病伴相关危险因素、或犬/猫存在>1种疾病或血栓危险因素。
- 临床可根据共识定义识别血栓低或中风险犬或猫:仅有单一危险因素或疾病,或已知危险因素疾病可能在治疗后数天至数周内消退。
- 原文指出这些疾病与血栓的关联为后续领域的处方推荐提供了基础。
指南或共识出处
- 共识名称:Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 1-Defining populations at risk.
- 发布机构:J Vet Emerg Crit Care (San Antonio)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Thrombosis is a well-recognized phenomenon in dogs and cats with a significant impact on morbidity and mortality. Despite growing awareness of thrombosis and increased use of antithrombotic therapy, there is little information in the veterinary literature to guide the use of anticoagulant and antiplatelet medications. The goal of Domain 1 was to explore the association between disease and thrombosis in a number of conditions identified as potential risk factors in the current veterinary literature, to provide the basis for prescribing recommendations.
DESIGN: A population exposure comparison outcome format was used to represent patient, exposure, comparison, and outcome. Population Exposure Comparison Outcome questions were distributed to worksheet authors who performed comprehensive searches, summarized the evidence, and created guideline recommendations that were reviewed by domain chairs. Revised guidelines then underwent the Delphi survey process to reach consensus on the final guidelines. Diseases evaluated included immune-mediated hemolytic anemia, protein-losing nephropathy, pancreatitis, glucocorticoid therapy, hyperadrenocorticism, neoplasia, sepsis, cerebrovascular disease, and cardiac disease.
SETTINGS: Academic and referral veterinary medical centers.
RESULTS: Of the diseases evaluated, a high risk for thrombosis was defined as dogs with immune-mediated hemolytic anemia or protein-losing nephropathy, cats with cardiomyopathy and associated risk factors, or dogs/cats with >1 disease or risk factor for thrombosis. Low or moderate risk for thrombosis was defined as dogs or cats with a single risk factor or disease, or dogs or cats with known risk factor conditions that are likely to resolve in days to weeks following treatment.
CONCLUSIONS: Documented disease associations with thrombosis provide the basis for recommendations on prescribing provided in subsequent domains. Numerous knowledge gaps were identified that represent opportunities for future study.
参考来源
- deLaforcade A, Bacek L, Blais MC, et al. Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 1-Defining populations at risk. J Vet Emerg Crit Care (San Antonio). 2019. PMID: 30654424. doi:10.1111/vec.12797
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。